Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) FCF Margin (2020 - 2024)

Barinthus Biotherapeutics filings provide 5 years of FCF Margin readings, the most recent being 122.33% for Q3 2024.

  • On a quarterly basis, FCF Margin changed N/A to 122.33% in Q3 2024 year-over-year; TTM through Dec 2025 was 320.77%, a 12148.0% decrease, with the full-year FY2024 number at 199.29%, up 616131.0% from a year prior.
  • FCF Margin hit 122.33% in Q3 2024 for Barinthus Biotherapeutics, up from 4555.69% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 839600.0% in Q4 2021 to a low of 40691.43% in Q2 2021.
  • Median FCF Margin over the past 5 years was 474.76% (2020), compared with a mean of 51476.3%.
  • Biggest five-year swings in FCF Margin: skyrocketed 84103814bps in 2021 and later crashed -83978475bps in 2022.
  • Barinthus Biotherapeutics' FCF Margin stood at 1438.14% in 2020, then soared by 58481bps to 839600.0% in 2021, then tumbled by -100bps to 184.75% in 2022, then plummeted by -2366bps to 4555.69% in 2023, then soared by 97bps to 122.33% in 2024.
  • The last three reported values for FCF Margin were 122.33% (Q3 2024), 4555.69% (Q2 2023), and 1158.33% (Q1 2023) per Business Quant data.